12月24日，有一只新股上市，为科创板的健信超导（688805.SH）。该公司成立于2013年12月11日，主 要从事医用磁共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和 梯度线圈，这三大类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 Est Un Descrip | | | 今日上市 | | | --- | --- | --- | --- | | | 688805.SH 健信超导 | | | | 发行价(元/股) | 机构报价(元/股) | 市值(亿元) | 所属行业 | | 18.58 | 18.89 | 31.15 | 医疗仪器设备及器 | | | | | 械制造 | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | | | 联影医疗 | 60.39 | | 61.97 | 31.79 | 辰光医疗 | 亏损 | | | | 奕瑞科技 | 40.38 | | | 业绩情况 | | | | 5.0 4.5 | | | 50% | | 4.0 | | | 40% | | 3.5 3.0 - | | | 30% | 不过，当前健信超 ...

12月15日，可申购科创板的健信超导(688805.SH)。该公司成立于2013年12月11日，主要从事医用磁共 振成像(MRI)设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和梯度线圈，这三大 类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 公司是全球最大的超导磁体独立供应商 注:机构报价为剔除无效报价和最高报价后,公募基金、社保基金、养老金、年金基金、保险资金和合格境外投 资者的报价中位数。 据招股书介绍，健信超导是国内最早规模化生产高场强超导磁体的厂商之一，并作为独立供应商保障了 国产磁共振产业的核心部件批量供应，有力推动了MRI设备国产化率提升。 目前，健信超导已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式 零挥发超导磁体在内的丰富产品矩阵，成为全球磁共振行业内排名第一的超导磁体独立供应商。 同时，作为全球领先的专业磁共振核心部件供应商，健信超导已与国内外知名MRI设备厂商如日本富士 胶片集团、美国GE医疗、意大利百胜医疗、万东医疗（600055）、深圳安科、联影医疗、福晴医疗等 建立了紧密的合作关系，并通过海外子公司布局及运输过 ...

12月15日，健信超导(688805.SH)开启申购，发行价格为18.58元/股，申购上限为1万股，市盈率61.97倍，属于上交所， 广发证券为其保荐人。 在永磁体领域，公司通过高性能磁性材料及高效磁路设计，并引入低涡流、高开放性等设计技术，可为客户提供产品 系列丰富的高质量永磁体，目前是全球规模最大的MRI设备永磁体供应商。永磁MRI设备具有经济性高、检查舒适度 高、设计灵活性强、低维护需求、能耗低等特点，便于基层医疗系统普及，同时在介入治疗和专业化应用领域具有优 势。 作为全球领先的专业磁共振核心部件供应商，公司已与国内外知名MRI设备厂商如日本富士胶片集团、美国GE医疗、 意大利百胜医疗、万东医疗（600055）、深圳安科、联影医疗、福晴医疗等建立了紧密的合作关系，并通过海外子公 司布局及运输过程液氦保持专利技术研发促进MRI设备海外供应链模式的创新，大幅降低了最终交付成本。公司产品 对应的MRI设备超过50%最终销往日本、欧美和其他海外新兴市场区域，推动MRI设备的全球推广。 财务方面，于2022年度、2023年度、2024年度及2025年1-6月，公司实现营业收入分别约为3.59亿元、4.51亿元、 ...

Group 1 - The core point of the article is the approval by the China Securities Regulatory Commission for Ningbo Jianxin Superconducting Technology Co., Ltd. to conduct its initial public offering (IPO) on the Shanghai Stock Exchange, with a fundraising target of 865 million yuan [1] - Jianxin Superconducting primarily engages in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils [1] - The company has developed a diverse product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, 3.0T zero-evaporation superconducting magnets, and open zero-evaporation superconducting magnets, making it the leading independent supplier of superconducting magnets in the global MRI industry [1]

Core Viewpoint - Ningbo Jianxin Superconductor Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board, positioning itself as the world's largest independent supplier of superconducting magnets for MRI equipment [1][2] Group 1: Company Overview - Jianxin Superconductor's IPO application was approved on October 21, with its review status updated to "submitted for registration" [1] - The company ranks fifth globally and second domestically in terms of market share for superconducting magnets used in MRI equipment, based on installed capacity [1] Group 2: Market Position and Technology - The company has closed a 20-year technology gap with international giants in the field of zero-evaporation superconducting technology, enhancing product performance and cost competitiveness through design and process innovation [2] - Jianxin Superconductor is one of the earliest manufacturers in China to scale up the production of high-field superconducting magnets, breaking the long-standing monopoly of European and Japanese manufacturers since 2015 [2] Group 3: Financial Performance - The company's revenue for the years 2022 to 2024 and the first half of 2025 is as follows: - 2022: 35.89 million yuan - 2023: 45.06 million yuan - 2024: 42.55 million yuan - 2025 (first half): 25.21 million yuan [2] - Net profit figures for the same periods are: - 2022: 3.46 million yuan - 2023: 4.87 million yuan - 2024: 5.58 million yuan - 2025 (first half): 3.19 million yuan [2] Group 4: Partnerships and Industry Impact - The company has established close partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and United Imaging Healthcare, contributing to the domestic MRI industry's core component supply [2]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has received approval for its IPO application on the Sci-Tech Innovation Board, with its review status updated to "submitted for registration" as of October 21 [1] Group 1: Market Position and Competitiveness - In terms of installed capacity, Jianxin Superconducting ranks fifth globally and second among domestic companies in the MRI superconducting magnet market for 2024, making it the largest independent supplier of superconducting magnets worldwide [1] - The company has established a comprehensive product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the top independent supplier in the global MRI industry [3] - Jianxin Superconducting has closed a 20-year technology gap with international giants in the zero-evaporation superconducting technology field and has continuously improved product performance and cost competitiveness through design and process innovation [3] Group 2: Financial Performance - The company's revenue for the periods from 2022 to 2024 and the first half of 2025 are as follows: 358.93 million yuan, 450.64 million yuan, 425.50 million yuan, and 252.10 million yuan respectively [4] - The net profit for the same periods is reported as 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan respectively [4] Group 3: Strategic Partnerships - Jianxin Superconducting has established close cooperative relationships with well-known MRI equipment manufacturers both domestically and internationally, including Fujifilm Holdings, GE Healthcare, and United Imaging Healthcare [3]